<DOC>
	<DOCNO>NCT00238199</DOCNO>
	<brief_summary>RATIONALE : Calcitriol may cause pancreatic cancer cell look like normal cell , grow spread slowly . Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop dividing . Calcitriol may also help docetaxel work well make tumor cell sensitive drug . Giving calcitriol together docetaxel may kill tumor cell . PURPOSE : This phase II trial study well give calcitriol together docetaxel work treat patient metastatic locally advanced pancreatic cancer .</brief_summary>
	<brief_title>Calcitriol Docetaxel Treating Patients With Metastatic Locally Advanced Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine time progression patient metastatic locally advanced pancreatic cancer treat calcitriol docetaxel . Secondary - Determine median one-year survival patient treat regimen . - Determine overall response patient treat regimen . - Determine toxic effect regimen patient . - Determine change pancreatic cancer-induced pain patient treat regimen . OUTLINE : Patients receive oral calcitriol day 1 , 8 , 15 docetaxel IV 15-30 minute day 2 , 9 , 16 . Courses repeat every 4 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis pancreatic cancer Locally advance metastatic disease PATIENT CHARACTERISTICS : Age Over 18 Performance status Eastern Cooperative Oncology Group ( ECOG ) 02 Life expectancy Not specify Hematopoietic White blood cell ( WBC ) &gt; 3,000/mm^3 Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin ≥ 8.0 g/dL ( transfusion allow ) Hepatic Bilirubin &lt; 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ( AP ) &lt; 5.0 time ULN Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) &lt; 2.5 time ULN ( AP &lt; 2.5 time ULN ) OR ALT AST &lt; 1.5 time ULN ( AP &gt; 2.5 time ULN &lt; 5.0 time ULN ) Renal Creatinine &lt; 1.3 mg/dL Calcium &lt; 10.5 mg/dL Phosphate &lt; 4.7 mg/dL No kidney stone within past 5 year No history hypercalcemia Cardiovascular No myocardial infarction within past 3 month No uncontrolled heart failure know ejection fraction &lt; 30 % No significant heart disease Other Not pregnant nursing Fertile patient must use effective contraception No hypersensitivity docetaxel drug formulate polysorbate 80 No peripheral neuropathy ≥ grade 2 No comorbid condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy metastatic disease No prior chemoradiotherapy locally advanced disease No prior adjuvant docetaxel Other prior adjuvant chemotherapy allow Endocrine therapy Not specify Radiotherapy See Chemotherapy More 2 week since prior radiotherapy Surgery More 30 day since prior investigational surgery Other More 7 day since prior concurrent digoxin thiazide diuretic therapy More 30 day since prior investigational therapy No concurrent magnesiumcontaining antacid , bile resinbinding drug , calcium supplement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>